| Literature DB >> 34975447 |
Rafael Casas1,2, Melissa Sandison1,2, Diane Nichols2, Kaelin Martin1, Khue Phan1, Tianyao Chen1, Peter S Lum1,2.
Abstract
We have developed a passive and lightweight wearable hand exoskeleton (HandSOME II) that improves range of motion and functional task practice in laboratory testing. For this longitudinal study, we recruited 15 individuals with chronic stroke and asked them to use the device at home for 1.5 h per weekday for 8 weeks. Subjects visited the clinic once per week to report progress and troubleshoot problems. Subjects were then given the HandSOME II for the next 3 months, and asked to continue to use it, but without any scheduled contact with the project team. Clinical evaluations and biomechanical testing was performed before and after the 8 week intervention and at the 3 month followup. EEG measures were taken before and after the 8 weeks of training to examine any recovery associated brain reorganization. Ten subjects completed the study. After 8 weeks of training, functional ability (Action Research Arm Test), flexor tone (Modified Ashworth Test), and real world use of the impaired limb (Motor Activity Log) improved significantly (p < 0.05). Gains in real world use were retained at the 3-month followup (p = 0.005). At both post-training and followup time points, biomechanical testing found significant gains in finger ROM and hand displacement in a reaching task (p < 0.05). Baseline functional connectivity correlated with gains in motor function, while changes in EEG functional connectivity paralleled changes in motor recovery. HandSOME II is a low-cost, home-based intervention that elicits brain plasticity and can improve functional motor outcomes in the chronic stroke population.Entities:
Keywords: exoskeleton; hand; neurorehabilitation; stroke; therapy
Year: 2021 PMID: 34975447 PMCID: PMC8719001 DOI: 10.3389/fnbot.2021.773477
Source DB: PubMed Journal: Front Neurorobot ISSN: 1662-5218 Impact factor: 2.650
Comparison of exoskeletons for hand rehabilitation.
|
|
|
|
|
|---|---|---|---|
| XGlove | N/A | N/A | •Actuated device (Portable) |
| PneuGlove | N/A | N/A | •Pneumatic glove (Tethered-not portable) |
| Hand of Hope | 0.7 kg (small/med) 0.8 kg (large) | N/A | •Linear actuated (Tethered) |
| CyberGrasp | 0.45 kg (+0.8 kg with CyberGlove) | N/A | •Powered (Tethered) |
| HandMATE | 0.37 kg | N/A | •Actuated device (Portable) |
| HandSOME II | 0.25 kg | N/A | •Passive, assistive device (Portable) |
| HandSOME I | 0.22 kg | N/A | •Passive, assistive device (Portable) |
| SaeboGlove | N/A | $299 | •Passive, assistive device (Portable) |
| SaeboFlex | N/A | $599 | •Passive, assistive device (Portable) |
Figure 1(Left) Spring driven HandSOME II with adjustable screws. (Right) Springs paths for MCP and PIP/DIP springs.
Figure 2Typical Torque vs. Angle assistance curves for the MCP joint. The shape and peak torque change as the maximum spring length denoted in the legend is adjusted with the MCP knob. Similar profiles were applied to the PIP joint.
Figure 3CAD drawing showing locations of magnetometers and magnet during finger extension and flexion. The magnet orientation is affected by both MCP and PIP rotation.
Figure 4Subjects were seated in front of a testing table. Position A is the target location of the Nut-Pickup task, at shoulder height. Position B is the starting location of the nut. Position C is the start position for all tasks. Position D is the start location of the water bottle. The forward distances from the subject to positions B, C, and D were 11”, 6”, and 8” respectively. The forward distance to position A was determined by the length of the subject's outstretched arm at 90 deg of shoulder elevation and full elbow extension (at 100% of reach).
Participant characteristics.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 1 | 69 | M | Right BG, corona radiata | Ischemic | 67 | 39 | 32 |
| 2 | 47 | F | Left temporal and parietal lobes | Hemorrhage | 45 | 37 | 22 |
| 3 | 53 | F | Left MCA | Hemorrhage | 61 | 23 | 4 |
| 4 | 63 | M | Right pontine | Ischemic | 13 | 47 | 39 |
| 5 | 60 | M | Left MCA | Ischemic | 86 | 30 | 26 |
| 6 | 38 | M | Left basal ganglia | Infarct | 18 | 40 | 37 |
| 7 | 49 | F | Right lacunes of BG/corona radiata and parietal lobe | Infarct | 11 | 54 | 47 |
| 8 | 66 | M | Right MCA | Infarct | 72 | 34 | 34 |
| 9 | 39 | M | L basal ganglia | Infarct | 7 | 45 | 27 |
| 10 | 71 | F | Periventricular white matter (non-specific) | Ischemic | 10 | 44 | 30 |
MCA, middle cerebral artery; ARAT, Action Research Arm Test.
Individual gains in outcome measures.
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |||
| 1 | 8 | 8 | 1 | −1 | 0.41 | 0.09 | −0.38 | 0.00 | 79.8 | 14,118 |
| 2 | −2 | 5 | −4 | −3 | 0.13 | 0.15 | −0.25 | −0.38 | 48.4 | 15,224 |
| 3 | 3 | 5 | 0 | 0 | 0.11 | 0.53 | −0.25 | −0.38 | 53.7 | 6,940 |
| 4 | −3 | −3 | 3 | −1 | 0.51 | 0.40 | −0.13 | 0.00 | 44.0 | 8,330 |
| 5 | −3 | −1 | 4 | 2 | 0.92 | 0.75 | 0.13 | 0.13 | 61.7 | 5,918 |
| 6 | 5 | N/A | 10 | N/A | 0.40 | N/A | −0.38 | N/A | 33.3 | 3,178 |
| 7 | 8 | 2 | 10 | 0 | 2.20 | 1.34 | −0.63 | −0.75 | 84.4 | 61,418 |
| 8 | 13 | 9 | 4 | 4 | 0.14 | 0.83 | −0.38 | −0.38 | 65.7 | 8,590 |
| 9 | −2 | −2 | 0 | 0 | 0.20 | 0.51 | 0.13 | 0.25 | 42.5 | N/A |
| 10 | 1 | 8 | 6 | 9 | 0.81 | 1.74 | 0.00 | 0.00 | 134.0 | 22,804 |
FM, Fugl-Meyer Test; ARAT, Action Research Arm Test; ASH, Modified Ashworth Test.
Mean change (SD) and statistical analysis of clinical outcomes.
|
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|
| Fugl-Meyer | 38.8 | (9.0) | 41.6 | (10.5) | 42.7 | (9.3) | 0.084 | 0.147 | 0.055 |
| ARAT | 27.2 | (12.6) | 30.6 | (14.5) | 30.1 | (12.8) | 0.051 | 0.039 | 0.375 |
| Motor activity log | 1.39 | (0.61) | 1.97 | (0.80) | 2.02 | (0.84) | 0.004 | 0.018 | 0.005 |
| Ashworth-flexors | 1.21 | (0.51) | 1.00 | (0.57) | 1.00 | (0.61) | 0.034 | 0.022 | 0.155 |
| Ashworth-extensors | 0.15 | (0.26) | 0.23 | (0.27) | 0.26 | (0.30) | 0.157 | 0.111 | 0.095 |
| Grip strength (lbs) | 29.7 | (15.66) | 29.8 | (15.3) | 33.22 | (15.93) | 0.43 | 0.90 | 0.31 |
Summary of biomechanics data: mean (SD).
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
| ||||||
| Finger flexion max (deg) | 180.2 (19.5) | 188.5 (19.6) | 187.2 (14.0) | 0.566 | 0.229 | 0.580 |
| Finger extension deficit (deg) | 50.3 (45.5) | 38.2 (52.6) | 29.6 (39.0) | 0.323 | 0.233 | 0.189 |
| Finger ROM (deg) | 128.4 (51.0) | 148.2 (51.7) | 156.6 (43.4) | 0.020 | 0.031 | 0.001 |
|
| ||||||
| Thumb cmc abd max (deg) | 38.2 (16.9) | 44.4 (18.5) | 34.2 (10.0) | 0.218 | 0.322 | 0.321 |
| Thumb cmc add/abd ROM (deg) | 25.4 (12.9) | 37.9 (26.6) | 33.0 (13.3) | 0.338 | 0.216 | 0.311 |
|
| ||||||
| Finger extension deficit (deg) | 34.7 (28.7) | 28.4 (27.0) | 26.9 (32.0) | 0.564 | 0.362 | 0.636 |
| Finger ROM (deg) | 81.6 (21.9) | 86.7 (20.1) | 91.5 (33.0) | 0.615 | 0.389 | 0.526 |
| Thumb cmc abd max (deg) | 45.0 (20.3) | 49.1 (16.0) | 42.5 (16.8) | 0.280 | 0.240 | 0.506 |
| Thumb cmc add/abd ROM (deg) | 42.4 (18.1) | 42.8 (13.2) | 77.5 (36.3) | 0.002 | 0.944 | 0.011 |
| Hand displacement max (cm) | 39.7 (8.5) | 42.0 (9.8) | 41.3 (5.1) | 0.701 | 0.471 | 0.987 |
| Trunk displacement max (cm) | 13.0 (7.8) | 12.1 (8.3) | 9.3 (6.2) | 0.350 | 0.740 | 0.169 |
|
| ||||||
| Hand displacement max (cm) | 33.0 (14.7) | 42.5 (6.8) | 45.3 (8.6) | 0.013 | 0.046 | 0.043 |
| Trunk displacement max (cm) | 13.0 (5.4) | 13.5 (5.7) | 12.5 (4.5) | 0.945 | 0.800 | 0.770 |
Figure 5Change in resting state β coherence vs. change in MAL score, from pre to post-HandSOME II therapy. Greater increases in IF-CCP and IF-CF resting state coherence correlated with greater MAL gains (p = 0.006 and R2 = 0.92, and p = 0.108 and R2 = 0.64, respectively).
Figure 6Baseline resting state coherence vs. change in MAL score from pre to post-HandSOME II therapy. Greater baseline β IF-CF and CF-ICP resting state coherence correlated with greater MAL gains (p = 0.012, R2 = 0.84 and p = 0.006, R2 = 0.70, respectively).
Survey results.
|
|
| |
|---|---|---|
| Before the study, how many hrs/week did you work on upper extremity therapy? | 4.75 (4.50) h | |
| During the study, how many hrs/week did you work on upper extremity therapy without the device? | 4.75 (2.71) h | |
| During the study, how many hrs/week did you work on upper extremity therapy with the device? | 9.13 (5.67) h | |
| What are the pros and cons about this HandSOME II device? What did you like/not like about it? |
|
|
| •It helped | •Breaking | |
| What features would improve wearability (i.e., comfort and ease of use)? | •The thumb part | |
| What added features would improve your therapy routine? | •Regular calendar/email/text reminders for therapy exercises (3) | |
| Would you recommend this device to other stroke patients? | Seven out of eight gave higher than a 10 | |
| How much would you be willing to pay for the device? | $50–100 (4) $100–150 (2) $150–300 (2) | |
| Before this study, had you used the SAEBO? Have you continued to use it? | Yes (2) | |
| No (6) | ||
| During the 3 month period, how many hrs/week did you work on upper extremity therapy with the device? | 5.16 (4.05) h | |
| During the 3 month period, you would have used the device more if—. | •Nothing to add | |